FDA Staff Finds Intercept's Liver Drug Effective as Monotherapy

The U.S. Food and Drug Administration's staff reviewers on Tuesday supported the use of Intercept Pharmaceuticals Inc's liver drug as a monotherapy in patients who did not respond to standard-of-care treatment.